TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Grace Therapeutics ( (GRCE) ) has shared an update.
On November 13, 2025, Grace Therapeutics announced its second quarter 2026 financial results and business updates, highlighting the FDA’s acceptance for review of its New Drug Application (NDA) for GTx-104, with a PDUFA target date set for April 23, 2026. The company’s Phase 3 STRIVE-ON trial showed positive outcomes for GTx-104, and a new U.S. patent was granted for its IV dosing regimen, extending intellectual property protection to 2043. Financially, the company reported a net loss reduction due to decreased R&D expenses and secured additional funding through warrant exercises, estimating cash and cash equivalents at $20 million as of October 31, 2025.
The most recent analyst rating on (GRCE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Grace Therapeutics stock, see the GRCE Stock Forecast page.
Spark’s Take on GRCE Stock
According to Spark, TipRanks’ AI Analyst, GRCE is a Neutral.
Grace Therapeutics is navigating a challenging financial landscape, marked by no revenue and persistent operational losses, which are somewhat mitigated by a strong equity base and absence of debt. The stock shows positive technical momentum but is at risk of being overbought. The negative P/E ratio highlights the risk associated with the company’s current financial performance and lack of earnings. Strategic management is required to improve operational viability and financial sustainability.
To see Spark’s full report on GRCE stock, click here.
More about Grace Therapeutics
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing GTx-104, a novel injectable formulation of nimodipine for intravenous infusion. The company aims to address unmet medical needs in patients with aneurysmal subarachnoid hemorrhage (aSAH), a specific type of stroke.
Average Trading Volume: 78,626
Technical Sentiment Signal: Sell
Current Market Cap: $41.9M
See more data about GRCE stock on TipRanks’ Stock Analysis page.